Accuracy of a Portable International Normalized Ratio Monitor in Elderly Patients (AGINR)
|ClinicalTrials.gov Identifier: NCT01930916|
Recruitment Status : Unknown
Verified April 2014 by University Hospital, Caen.
Recruitment status was: Recruiting
First Posted : August 29, 2013
Last Update Posted : April 9, 2014
Oral anticoagulants vitamin K antagonists (VKA) have been used for many years in the treatment of thromboembolic disorders, which are among the most costly diseases in terms of public health resources. According to the Agence française de sécurité sanitaire des produits de santé (AFSSAPS), it was estimated at about 900,000 the number of patients treated with VKA in 2008 (more than 1% of the French population). VKA are at the origin of many adverse effects, given their narrow therapeutic window. They are the cause of the death of approximately 5000 patients per year. The use of this therapy is a priority axis of reflection for the Haute Autorité de Santé.
The interregion G4 (Nord Pas de Calais, Normandy, Picardy), with more than 9 million people, is particularly affected by this problem.
University hospitals of our interregion, given their very substantial regional referral activity, are actually involved in managing VKA adverse side effects.
Elderly population constitutes the majority of prescriptions. The main objective of this study is to compare INR of people older than 75 years measured by traditional method with those measured by capillary method with INRatio2 supply.
The secondary objective is to show that this measure is not affected by the presence or absence of anti-phospholipid antibodies, probably very prevalent in the elderly, as well as to test the variability of INR measurement between different hospital.
|Condition or disease||Intervention/treatment||Phase|
|Blood Coagulation Disorders Blood Coagulation Disorder With Prolonged Bleeding Time Blood Coagulation Disorder With Prolonged Coagulation Time||Device: INR capillary measurement with INRatio 2 device Other: antiphospholipid antibodies and lupus anticoagulant||Not Applicable|
Adverse effects of oral anticoagulants (warfarin, fluindione mainly) are bleeding complications and concern 13% of hospitalizations, approximately 17,000 admissions per year. They constitute 12.3% of iatrogenic adverse effect according to the latest results of the survey conducted by the haute autorité de santé (HAS). A study realized in 2000, with 2976 patients, shows that 28.8% of patients were outside of any therapeutic range (<2 or> 4.5). In 2003, a third of french biologists had no knowledge of the indication of VKA treatment of patients at the INR measurement, and more than fifty percent in 2000. When the therapeutic range was known, the value of the INR remained outside it in 30% of cases. The median time between INR equilibration phase was 5 to 6 days, while the recommended time is 2 to 4 days. A quarter of patients in phase equilibrium treatment did not have a measure of INR at least once a month. Followed over a period of a year, patients spent 40% of the time with a value of INR outside the therapeutic range, high-risk area of recurrent thrombosis or hemorrhage. That is why they require regular monitoring of INR.
Currently, this monitoring is done through a blood sample analyzed by a laboratory according to standard techniques.
The use of the INR measurement by capillary method provides a result in less than 3 minutes. This also allows the development of different monitoring strategies. In the context of a self-monitoring measure, the patient himself performs the test using the device and therapeutic adjustment is made by the health care professional.
Data analysis by HAS showed that the use of a self-measurement device significantly improved the time spent in the therapeutic range, reduced the risk of major bleeding and the accident major thromboembolism.
The pathologies treated by VKA are more common in the elderly. They are also more vulnerable to falls, overdoses of these treatments because their pharmacokinetics is amended by polypharmacy, malnutrition, less protein binding. The relative risk of bleeding is multiplicated by two beyond 70 years. Despite the emergence of new anticoagulants in the prevention of complications of arrhythmia (this disorder affect nearly 10% of the population aged over 80 years), VKA remains prevalent because these new drugs have renal elimination that can not be monitored, and can not be dialysable, have no antidote and represent a daily cost about 30 times the VKA.
The question of the use of devices for self-measurement of INR in the elderly is particularly timely, because this population has never had, to our knowledge, a specific evaluation of this technique.
Elderly population would derive the greatest benefit of this system because it will significantly improve the time spend in the therapeutic range, and reduce the risk of bleeding and thromboembolic events in reducing INR fluctuations.
We build a multicenter study whose main objective is to demonstrate the concordance of INR measurement by the capillary way (INRatio2 ®, SAS ALERE, Jouy-en-Josas) with venous technical reference. It concerns patients older than 75 years treated with VKA and hospitalized in Internal Medicine, Geriatrics and Vascular Medicine in the fours university hospital of the G4 region. The secondary objectives are to estimate the prevalence of antiphospholipid antibodies (ranging from 12 to 55% depending on the study) and their influence on the measurement of the INR by capillary method and the variability of the INR veinous measurement in function of the hospital, with a centralized INR measurement which allow to compare. 150 patients is required to perform this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Accuracy of a Portable International Normalized Ratio Monitor in a Population Aged 75 Years Old and Over|
|Study Start Date :||October 2012|
|Estimated Primary Completion Date :||November 2014|
|Estimated Study Completion Date :||December 2014|
INR capillary measurement with INRatio 2 device antiphospholipid antibodies and lupus anticoagulant
Device: INR capillary measurement with INRatio 2 device
INR capillary measurement with INRatio 2 deviceOther: antiphospholipid antibodies and lupus anticoagulant
Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
- INR by capillary method and INR by veinous punction [ Time Frame: 24 hours ]
INR by the classical way (punction) and comparison with a capillary method tested here.
INR by capillary method is done immediately after inclusion. INR by veinous punction is done on the 24 hours after the inclusion.
- Difference between International normalized ratio (INR) measured in a veinous blood punction and with a capillary method on the same patient and correlated to the level of phospholipid antibodies and lupus anti coagulant [ Time Frame: 1 year ]
We want to know if the level of lupus and anti cardiolipin antibodies influence the value of INR measured by capillary method.
lupus and anti cardiolipin antibodies tubes will be frozen after punction and analysed up to 1 year after.
- Difference of INR measurement by veinous method between Caen laboratory and the local center laboratory. [ Time Frame: 1 year ]
INR of a patient will be measured in two different center (Caen is the reference center).
Blood sample will be frozen after punction and analysed up to 1 year after.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01930916
|Contact: Boris Bienvenu, M.D, Ph.D||+33 (0)2 31 06 45 email@example.com|
|Centre hospitalier régional universitaire d'Amiens||Not yet recruiting|
|Amiens, France, 80054|
|Contact: Marie-Antoinette Sevestre, M.D,Ph.D + 33 3 22 45 59 30 firstname.lastname@example.org|
|Principal Investigator: Marie-antoinette Sevestre, M.D, Ph.D|
|Sub-Investigator: Pierre Jouanny, M.D,Ph.D|
|Sub-Investigator: Jean-Francois Claisse, M.D|
|Centre hospitalier régional universitaire de Caen||Recruiting|
|Caen, France, 14000|
|Contact: Boris Bienvenu, M.D,Ph.D +33 (0)2 31 06 45 84 email@example.com|
|Principal Investigator: boris bienvenu, M.D,Ph.D|
|Sub-Investigator: laurent Auboire, M.D|
|Sub-Investigator: brigitte le mauff, M.D,Ph.D|
|Sub-Investigator: Pablo Descatoire, M.D|
|Centre hospitalier régional universitaire de Lille||Not yet recruiting|
|Lille, France, 59000|
|Contact: Marc Lambert, M.D,Ph.D +33 3 20 44 42 96 firstname.lastname@example.org|
|Principal Investigator: marc lambert, M.D,Ph.D|
|Sub-Investigator: Francois Puisieux, M.D,Ph.D|
|Sub-Investigator: Eric Boulanger, M.D,Ph.D|
|Centre hospitalier régional universitaire de Rouen||Not yet recruiting|
|Rouen, France, 76000|
|Contact: Ygal Benhamou, M.D email@example.com|
|Principal Investigator: Ygal Benhamou, M.D|
|Sub-Investigator: Jeanne Yvonne BORG, M.D,Ph.D|
|Sub-Investigator: Philippe Chassagne, M.D,Ph.D|
|Principal Investigator:||Boris Bienvenu, M.D,Ph.D||Centre hospitalier régional universitaire de Caen|
|Study Director:||Jean Jacques Dutheil||Centre hospitalier régional universitaire de Caen|
|Study Chair:||Laurent Auboire, M.D||Centre hospitalier régional universitaire de Caen|